中国专家团队最新研究成果：晚期胆管癌治疗有效率提升至75%

Core Insights - The article discusses a significant breakthrough in the treatment of advanced cholangiocarcinoma, highlighting a new therapy that dramatically improves patient outcomes [3][4]. Group 1: Clinical Research Findings - A Phase II clinical study led by Professor Wang Peng's team reported an objective response rate (ORR) of 75% for patients with advanced intrahepatic cholangiocarcinoma who failed first-line treatment, compared to approximately 5% previously [3]. - The median progression-free survival (PFS) increased from 2-4 months to 16.8 months, while the overall survival (OS) reached 25.4 months, indicating a substantial improvement in treatment efficacy [3]. - The study utilized a combination of cryoablation, targeted therapy, and immunotherapy, which collectively enhanced the clinical outcomes for patients [3]. Group 2: Future Research and Development - A follow-up multi-center, randomized, controlled clinical study has been initiated to further validate the findings and potentially fill the current gap in effective second-line treatment options for cholangiocarcinoma [4]. - The goal of this subsequent research is to provide higher-level evidence for clinical practice guidelines, thereby improving treatment protocols for cholangiocarcinoma patients [4]. Group 3: Collaboration and Innovation - The establishment of the "Shanghai International Medical Science and Technology Innovation Center - Tumor Precision Intervention Excellence Innovation Center" aims to accelerate the industrialization of medical breakthroughs and enhance the translation of research into clinical practice [6]. - The center will focus on the validated "liver tumor cryoablation" technique and prioritize clinical trials for products developed through this collaboration, promoting a deep integration of medical and engineering disciplines [6].